⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 9, 2024Neurology

Effectiveness and Safety of Transitioning to Ravulizumab from Eculizumab in Patients with Generalized Myasthenia Gravis: Evidence from a Global Registry (P10-11.002)

Guido Sabatella Andrew M. Gordon Pushpa Narayanaswami Michael Pulley Saida R. Sharapova James F. Howard

View Full Paper

Ask AI

Bookmark

Share

Abstract

To assess the effectiveness and safety of transitioning patients with generalized myasthenia gravis (gMG) from eculizumab to ravulizumab treatment in clinical practice using the Myasthenia Gravis Activities of Daily Living (MG-ADL) total score and Myasthenia Gravis Foundation of America (MGFA) classification.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sabatella et al. (2024) studied this question.

synapsesocial.com/papers/68e6fdb8b6db643587678371 https://doi.org/10.1212/wnl.0000000000204425

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Real‐world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis2024 · 25 citations
2Ravulizumab use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice2024 · 10 citations
3Impact of Prior Intravenous Immunoglobulin and Plasmapheresis on Eculizumab or Ravulizumab Treatment for Generalized Myasthenia Gravis: An Analysis of the <scp>MG SPOTLIGHT</scp> Registry2025 · 2 citations
4Comparing the Efficacy of Ravulizumab Versus Efgartigimod Among AChR-AB Positive Generalized Myasthenia Gravis (P9-9.009)Original Research · 2026
5Patient Satisfaction With Ravulizumab Treatment for Generalized Myasthenia Gravis (gMG) in the United States (US) (P11-9.003)Original Research · 2026